Mesoblast FY26 net loss narrows 44% to US$57.5 million; revenue more than doubled to US$120.3 million
Reuters2026/08/27 00:32- Mesoblast posted FY2026 revenue of US$120.3 million, up from US$17.2 million a year earlier, on Ryoncil launch momentum.
- Net loss narrowed 44% to US$57.5 million; gross profit rose to US$103.6 million as product sales climbed to US$115.2 million.
- R&D expense increased to US$97.5 million; selling, general and administration costs rose to US$57.3 million.
- Net operating cash spend was US$43.8 million; cash and cash equivalents ended at US$103 million following a US$125 million credit-line facility.
- Management flagged Phase 3 treatment completion for rexlemestrocel-L in chronic low back pain, with top-line results expected mid-CY2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million
TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Crypto prices
More
